The Opren Scandal
Presented by Fred Emery 2: Selling the Product
Last week's Panorama showed how evidence of the serious side-effects of the new anti-arthritis drug, Opren, was suppressed or ignored even after people using it had begun to die. This week's investigation reveals how much money is at stake in the arthritis business and how hard-sales policies have dangerous side-effects of their own. Tom Mangold reports on the close relationships between drug companies and their most important customers - the doctors; on the inadequacies in the regulations that should protect patients from the conflict of interests that can arise.
Producer JANE DRABBLE Editor GEORGE CAREY